½ÃÀ庸°í¼­
»óǰÄÚµå
1600661

Áö¼ÓÇü ½Å´ëü¿ä¹ý(CRRT) ½ÃÀå : Á¦Ç°, ¾ç½Ä, ¿¬·É´ë, ÀûÀÀÁõ, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Continuous Renal Replacement Therapy Market by Product, Modality, Age Group, Indication, End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 199 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Áö¼ÓÀû ½Å´ëü¿ä¹ý(CRRT) ½ÃÀåÀº 2023³â¿¡ 142¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 154¾ï 9,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 8.55%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â¿¡´Â 253¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

Áö¼ÓÀû ½Å´ëü¿ä¹ý(CRRT)Àº ÁÖ·Î ÁßȯÀڽǿ¡¼­ ±Þ¼º ½ÅºÎÀü ȯÀÚ¸¦ Áö¿øÇϱâ À§ÇØ »ç¿ëµÇ´Â ÀÇ·á ½Ã¼ú·Î, 24½Ã°£ µ¿¾È Áö¼ÓÀûÀ¸·Î Ç÷¾×À» Á¤È­ÇÏ¿© ÀüÇØÁú ±ÕÇüÀ» À¯ÁöÇϸ鼭 ³ëÆó¹°°ú °úµµÇÑ ¼öºÐÀ» Á¦°ÅÇϸç, CRRTÀÇ Çʿ伺Àº ±âÁ¸ÀÇ Ç÷¾× Åõ¼®À» °ßµô ¼ö ¾ø´Â ÁßÁõ ȯÀÚ¿¡¼­ ¹ß»ýÇϸç, ÆÐÇ÷Áõ, ´Ù¹ß¼º Àå±âºÎÀü ¹× ±âŸ Áúȯ¿¡ ÇʼöÀûÀÔ´Ï´Ù. CRRTÀÇ Çʿ伺Àº ±âÁ¸ÀÇ Ç÷¾×Åõ¼®À» °ßµô ¼ö ¾ø´Â ÁßÁõ ȯÀÚ¿¡°Ô ¹ß»ýÇϸç, ÆÐÇ÷Áõ, ´ÙÀå±â ºÎÀü µîÀÇ º´Áõ¿¡ ÇʼöÀûÀ̸ç, CRRTÀÇ ¿ëµµ´Â ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡ °ÉÃÄ ÀÖÁö¸¸ ÁÖ·Î º´¿ø, ÁßȯÀÚ½Ç, Àü¹® Ŭ¸®´Ð¿¡¼­ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ÃÖÁ¾ »ç¿ë ¹üÀ§¿¡´Â ÁÖ·Î ÁßȯÀÚ½Ç ½Ã¼³À» °®Ãá º´¿øÀÌ Æ÷ÇԵǸç, ÀÇ·á ÀÎÇÁ¶ó°¡ °³¼±µÊ¿¡ µû¶ó ½ÅÈï±¹¿¡¼­ ¼ö¿ä°¡ Áõ°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 142¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 154¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 253¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 8.55%

±Þ¼º ½ÅºÎÀü ¹ß»ý·ü Áõ°¡, CRRT ±â¼úÀÇ ¹ßÀü, ´ç´¢º´°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ½ÃÀå È®´ë´Â ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í ÷´Ü ÀÇ·á¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÀÇÇØ ´õ¿í ÃËÁøµÉ °ÍÀÔ´Ï´Ù. ±×·¯³ª ³ôÀº ¿î¿µ ºñ¿ë, ¼÷·ÃµÈ ÀηÂÀÇ Çʿ伺, °¨¿°°ú °°Àº ÇÕº´Áõ À§ÇèÀº ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ºñ¿ë È¿À²ÀûÀÎ CRRT Àåºñ¿Í ÀÇ·áÁøÀ» À§ÇÑ Á¾ÇÕÀûÀÎ ±³À° ÇÁ·Î±×·¥À» °³¹ßÇÏ¸é º¸´Ù Æø³ÐÀº µµÀÔÀ» ÃËÁøÇÏ°í ±â¼ú °ÝÂ÷ ¹®Á¦¸¦ ÇØ°áÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿¬±¸ ¹× Çõ½Å ºÐ¾ß¿¡´Â CRRT ÀåºñÀÇ È¿À²¼º Çâ»ó, ȯÀÚ °á°ú¸¦ ÃÖÀûÈ­Çϱâ À§ÇÑ ½Ç½Ã°£ µ¥ÀÌÅÍ ¸ð´ÏÅ͸µÀ» À§ÇÑ AI ÅëÇÕ, ´õ ³ÐÀº ÀÀ¿ëÀ» À§ÇÑ ÈÞ´ë¿ë CRRT ÀåºñÀÇ Å½»ö µîÀÌ Æ÷ÇԵ˴ϴÙ. º¸´Ù È¿À²ÀûÀÎ »ýü ÀûÇÕ¼º Àç·á¿Í ÀÚµ¿ CRRT ½Ã½ºÅÛ¿¡ ´ëÇÑ ¿¬±¸°¡ ÁøÇà ÁßÀ̸ç, ½ÃÀåÀº Å©°Ô ¼ºÀåÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù. ±â¾÷µéÀº È®Àå °¡´ÉÇÑ ±â¼ú ¼Ö·ç¼Ç¿¡ ÅõÀÚÇϰí ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿Í Çù·ÂÇÏ¿© ¸ÂÃãÇü ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀå ħÅõ¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ºñÁî´Ï½º ±âȸ´Â dzºÎÇÏÁö¸¸, ±ÔÁ¦ Áؼö¸¦ À¯ÁöÇϰí ȯÀÚ ¾ÈÀüÀ» Áß½ÃÇÏ´Â °ÍÀº ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼ÒµéÀ» Á¾ÇÕÇϸé, CRRT ½ÃÀåÀº °æÀïÀÌ Ä¡¿­ÇÏ°í º¹ÀâÇÏÁö¸¸ Àü·«Àû Çõ½Å°ú ÀûÀÀÀ» ÅëÇØ ¼ºÀåÇÒ ¼ö ÀÖ´Â ±æÀÌ ¸¹´Ù´Â °ÍÀ» ¾Ë ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Áö¼ÓÇü ½ÅÀå´ëü¿ä¹ý ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® ÆÄ¾ÇÇϱâ

Áö¼ÓÀû ½ÅÀå ´ëü¿ä¹ý ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ±Þ¼º ½ÅÀå ¼Õ»ó(AKI) ¹× ¸¸¼º ½ÅÀå Áúȯ(CKD) Áõ°¡
    • ¼Ò¾Æ ¹× ½Å»ý¾Æ ȯÀÚ¸¦ À§ÇÑ °³¼±µÈ CCRT ½Ã½ºÅÛ Á¦°ø °¡´É¼º
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Áö¼ÓÀûÀÎ ½ÅÀå ´ëü ¿ä¹ý ½Ã¼úÀÇ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • CRRTÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» ³ôÀ̱â À§ÇÑ Áö¼ÓÀûÀÎ ¿¬±¸ ¹× °³¹ß
    • CRRT Àåºñ ¹× ±â¼ú¿¡ ´ëÇÑ Á¤ºÎÀÇ ¿ìÈ£ÀûÀÎ ½ÂÀÎ
  • ½ÃÀå °úÁ¦
    • Áö¼ÓÀû ½ÅÀå ´ëü ¿ä¹ý¿¡ µû¸¥ ±â¼úÀû ÇÕº´Áõ

Portre's Five Forces: Áö¼ÓÇü ½ÅÀå´ëü¿ä¹ý ½ÃÀåÀ» Ž»öÇÏ´Â Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Áö¼ÓÇü ½Å´ëü¿ä¹ý(CRRT) ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Áö¼ÓÇü ½ÅÀå´ëü¿ä¹ý ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Áö¼ÓÇü ½Å´ëü¿ä¹ý(CRRT) ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

Áö¼ÓÀû ½ÅÀå ´ëü ¿ä¹ý ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º Áö¼ÓÇü ½Å´ëü¿ä¹ý(CRRT) ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Áö¼ÓÇü ½ÅÀå´ëü¿ä¹ý ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀº º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æ¿¡ ´ëÇÑ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå Áö¼ÓÇü ½Å´ëü¿ä¹ý(CRRT) ½ÃÀå : Á¦Ç°º°

  • CRRT ½Ã½ºÅÛ
  • Åõ¼®¾× ¹× º¸Ãæ¾×
  • ÀÏȸ¿ë
    • ¹Ùµð¶óÀÎ ¼¼Æ® ¹× Æ©ºê
    • Ç÷¾× ¿©°ú±â

Á¦7Àå Áö¼ÓÇü ½Å´ëü¿ä¹ý(CRRT) ½ÃÀå : ¸ð´Þ¸®Æ¼º°

  • Áö¼Ó Á¤¸Æ Ç÷¾× ¿©°ú Åõ¼®
  • Áö¼Ó Á¤¸Æ Ç÷¾× Åõ¼®
  • Áö¼ÓÀû Á¤¸Æ Ç÷¾× ¿©°ú
  • Àú¼Ó ¿¬¼Ó ÇÑ¿Ü ¿©°ú

Á¦8Àå Áö¼ÓÇü ½Å´ëü¿ä¹ý(CRRT) ½ÃÀå : ¿¬·ÉÃþº°

  • ¼ºÀÎ
  • ¼Ò¾Æ°ú

Á¦9Àå Áö¼ÓÇü ½Å´ëü¿ä¹ý(CRRT) ½ÃÀå : ÀûÀÀÁõº°

  • ºñ½ÅÀå
  • ½ÅÀå

Á¦10Àå Áö¼ÓÇü ½Å´ëü¿ä¹ý(CRRT) ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Åõ¼® Ŭ¸®´Ð
  • ȨÄɾî
  • º´¿ø

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ Áö¼ÓÇü ½Å´ëü¿ä¹ý(CRRT) ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Áö¼ÓÇü ½Å´ëü¿ä¹ý(CRRT) ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Áö¼ÓÇü ½Å´ëü¿ä¹ý(CRRT) ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸®½ºÆ®

  • Joline GmbH & Co. KG
  • Infomed SA
  • Anjue Medical Equipment Co., Ltd.
  • Medites Pharma spol. s.r.o
  • Baxter International Inc.
  • SB-KAWASUMI LABORATORIES, INC.
  • Shionogi & Company, Limited
  • B. Braun SE
  • Medtronic PLC
  • Thermo Fisher Scientific Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • DIAMED Medizintechnik GmbH
  • Biomedica Medizinprodukte GmbH
  • Nextkidney B.V.
  • Asahi Kasei Medical Co., Ltd.
  • Nipro Corporation
  • Ningbo Tianyi Medical Devices Co., Ltd.
  • Braun & Co. Limited
  • Quanta Dialysis Technologies Limited
  • Miromatrix Medical Inc.
  • Sphingotec GmbH
  • CytoSorbents Corporation
  • Toray Medical Co., Ltd. by Toray Industries, Inc.
  • Nuwellis, Inc.
  • SWS Hemodialysis Care Co. Ltd.
  • Nikkiso Co., Ltd.
LSH

The Continuous Renal Replacement Therapy Market was valued at USD 14.28 billion in 2023, expected to reach USD 15.49 billion in 2024, and is projected to grow at a CAGR of 8.55%, to USD 25.37 billion by 2030.

Continuous Renal Replacement Therapy (CRRT) is a medical procedure used primarily in intensive care units to support patients with acute kidney injury. The procedure continuously purifies the blood over 24 hours, removing waste products and excess fluid while maintaining electrolyte balance. The necessity of CRRT arises in critically ill patients unable to tolerate conventional hemodialysis, making it essential for conditions such as sepsis and multiple organ failures. Its application extends across various medical settings but is predominantly utilized in hospitals, critical care units, and specialty clinics. The end-use scope primarily involves hospitals equipped with intensive care facilities, with potential demand increase in developing countries as medical infrastructures improve.

KEY MARKET STATISTICS
Base Year [2023] USD 14.28 billion
Estimated Year [2024] USD 15.49 billion
Forecast Year [2030] USD 25.37 billion
CAGR (%) 8.55%

Growing incidences of acute kidney failure, advances in CRRT technology, and the rising prevalence of chronic conditions like diabetes are key market growth factors. Market expansion is further propelled by increased healthcare spending and government initiatives towards advanced medical procedures. However, high operational costs, the requirement for skilled personnel, and risk of complications such as infections challenge market growth. An opportunity lies in developing cost-effective CRRT machines and comprehensive training programs for healthcare providers, which can encourage wider adoption and address skill gap issues.

Research and innovation areas include enhancing the efficiency of CRRT machines, integrating AI for real-time data monitoring to optimize patient outcomes, and exploring portable CRRT devices for wider application. The market is poised for significant growth with ongoing research into more efficient biocompatible materials and automated CRRT systems. For businesses, investing in scalable technology solutions and collaborating with healthcare providers for customized solutions could enhance market penetration. While opportunities abound, maintaining regulatory compliance and focusing on patient safety are indispensable. These elements collectively suggest that the CRRT market, while competitive and complex, offers numerous avenues for growth through strategic innovation and adaptation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Continuous Renal Replacement Therapy Market

The Continuous Renal Replacement Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of acute kidney injury (AKI) and chronic kidney diseases (CKD)
    • Availability of improved CCRT systems for pediatric and neonatal patients
  • Market Restraints
    • High cost of continuous renal replacement therapy procedure
  • Market Opportunities
    • Ongoing research and development for enhanced safety and efficacy of CRRT
    • Favorable government approvals for CRRT machines and techniques
  • Market Challenges
    • Technical complications associated with continuous renal replacement therapy

Porter's Five Forces: A Strategic Tool for Navigating the Continuous Renal Replacement Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Continuous Renal Replacement Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Continuous Renal Replacement Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Continuous Renal Replacement Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Continuous Renal Replacement Therapy Market

A detailed market share analysis in the Continuous Renal Replacement Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Continuous Renal Replacement Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Continuous Renal Replacement Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Continuous Renal Replacement Therapy Market, highlighting leading vendors and their innovative profiles. These include Joline GmbH & Co. KG, Infomed SA, Anjue Medical Equipment Co., Ltd., Medites Pharma spol. s.r.o, Baxter International Inc., SB-KAWASUMI LABORATORIES, INC., Shionogi & Company, Limited, B. Braun SE, Medtronic PLC, Thermo Fisher Scientific Inc., Fresenius Medical Care AG & Co. KGaA, DIAMED Medizintechnik GmbH, Biomedica Medizinprodukte GmbH, Nextkidney B.V., Asahi Kasei Medical Co., Ltd., Nipro Corporation, Ningbo Tianyi Medical Devices Co., Ltd., Braun & Co. Limited, Quanta Dialysis Technologies Limited, Miromatrix Medical Inc., Sphingotec GmbH, CytoSorbents Corporation, Toray Medical Co., Ltd. by Toray Industries, Inc., Nuwellis, Inc., SWS Hemodialysis Care Co. Ltd., and Nikkiso Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Continuous Renal Replacement Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across CRRT Systems, Dialysates & Replacement Fluids, and Disposables. The Disposables is further studied across Bodyline sets & tubes and Hemofilters.
  • Based on Modality, market is studied across Continuous Venovenous Hemodiafiltration, Continuous Venovenous Hemodialysis, Continuous Venovenous Hemofiltration, and Slow Continuous Ultrafiltration.
  • Based on Age Group, market is studied across Adults and Pediatrics.
  • Based on Indication, market is studied across Non-renal and Renal.
  • Based on End User, market is studied across Dialysis Clinics, Homecare, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of acute kidney injury (AKI) and chronic kidney diseases (CKD)
      • 5.1.1.2. Availability of improved CCRT systems for pediatric and neonatal patients
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of continuous renal replacement therapy procedure
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development for enhanced safety and efficacy of CRRT
      • 5.1.3.2. Favorable government approvals for CRRT machines and techniques
    • 5.1.4. Challenges
      • 5.1.4.1. Technical complications associated with continuous renal replacement therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing prevalence toward acute kidney injury (AKI) boosting a need for CRRT devices for seamless treatment procedures
    • 5.2.2. Modality: Utilization of continuous venovenous hemodiafiltration for liberal fluid management in renal therapies
    • 5.2.3. Age Group: Differing CRRT requirements among pediatric population
    • 5.2.4. Indication: Growing adoption of non-renal indications in extracorporeal renal therapies
    • 5.2.5. End User: Increasing uses of CRRT devices in hospitals to cater a patients need
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Continuous Renal Replacement Therapy Market, by Product

  • 6.1. Introduction
  • 6.2. CRRT Systems
  • 6.3. Dialysates & Replacement Fluids
  • 6.4. Disposables
    • 6.4.1. Bodyline sets & tubes
    • 6.4.2. Hemofilters

7. Continuous Renal Replacement Therapy Market, by Modality

  • 7.1. Introduction
  • 7.2. Continuous Venovenous Hemodiafiltration
  • 7.3. Continuous Venovenous Hemodialysis
  • 7.4. Continuous Venovenous Hemofiltration
  • 7.5. Slow Continuous Ultrafiltration

8. Continuous Renal Replacement Therapy Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Pediatrics

9. Continuous Renal Replacement Therapy Market, by Indication

  • 9.1. Introduction
  • 9.2. Non-renal
  • 9.3. Renal

10. Continuous Renal Replacement Therapy Market, by End User

  • 10.1. Introduction
  • 10.2. Dialysis Clinics
  • 10.3. Homecare
  • 10.4. Hospitals

11. Americas Continuous Renal Replacement Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Continuous Renal Replacement Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Continuous Renal Replacement Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. B. Braun Receives FDA Clearance for AQUAbase nX Reverse Osmosis System
    • 14.3.2. Quanta Receives FDA 510(k) Clearance for Expanded Indication of Continuous Renal Replacement Therapies
    • 14.3.3. Rockwell Medical Announces 3-Year Co-Promotional Collaboration with B. Braun Medical
    • 14.3.4. Nuwellis, DaVita partner on ultrafiltration therapy pilot program
    • 14.3.5. Baxter, Miromatrix Partner on Liver Failure Research
    • 14.3.6. PBMC Launches New Renal Therapy Option for Dialysis Patients
    • 14.3.7. SeaStar Medical, Nuwellis Partner on Kidney Injury Treatment
    • 14.3.8. Spectral Medical Announces Strategic Joint Venture with Infomed to Accelerate Commercialization of DIMI and SAMI Dialysis Devices.
    • 14.3.9. Baxter Announces U.S. FDA Clearance of ST Set Used to Help Treat Acute Kidney Injury Patients in the Hospital

Companies Mentioned

  • 1. Joline GmbH & Co. KG
  • 2. Infomed SA
  • 3. Anjue Medical Equipment Co., Ltd.
  • 4. Medites Pharma spol. s.r.o
  • 5. Baxter International Inc.
  • 6. SB-KAWASUMI LABORATORIES, INC.
  • 7. Shionogi & Company, Limited
  • 8. B. Braun SE
  • 9. Medtronic PLC
  • 10. Thermo Fisher Scientific Inc.
  • 11. Fresenius Medical Care AG & Co. KGaA
  • 12. DIAMED Medizintechnik GmbH
  • 13. Biomedica Medizinprodukte GmbH
  • 14. Nextkidney B.V.
  • 15. Asahi Kasei Medical Co., Ltd.
  • 16. Nipro Corporation
  • 17. Ningbo Tianyi Medical Devices Co., Ltd.
  • 18. Braun & Co. Limited
  • 19. Quanta Dialysis Technologies Limited
  • 20. Miromatrix Medical Inc.
  • 21. Sphingotec GmbH
  • 22. CytoSorbents Corporation
  • 23. Toray Medical Co., Ltd. by Toray Industries, Inc.
  • 24. Nuwellis, Inc.
  • 25. SWS Hemodialysis Care Co. Ltd.
  • 26. Nikkiso Co., Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦